RE:RE:RE:RE:RE:I sure like this JonIn all the material I've studied, G1945V, there has been no concern expressed about the transport of bacteria, viruses or other material across the BBB through receptor mediated transcytosis (RMT) once the receptor is populated with its intended ligand.
Some viruses can enter cells through receptor mediated endocytosis but that happens in competition with other ligands and not in concert with them. The smallest viral particles are about the same size as the largest proteins. I've never read anywhere that a virus can attach itself to a protein and be carried into a cell as an attachment to the protein.
The medically attractive nature of RMT is that it does not disrupt the BBB. Receptors are very selective and allow the transport of matching proteins. I think you've asked a good question but it may be a stretch to think that disease risks would be increased with xB3 RMT. I think it more likely that off-target issues with the LRP-1 receptors in the CNS would be a bigger issue.
This is a stretch opinion on my part. To my knowledge, Denali has never discussed it as a problem and I've never had cause to directly study the question. Certainly, if Bioasis knew there were problems of this or any other mature, they should be discussing it in their filings regarding the potential risks associated with xB3.
jd